drugset
Drugs / Multi-peptide CMV-Modified Vaccinia Ankara Vaccine
last change May 2026 re-read 9 days ago

Multi-peptide CMV-Modified Vaccinia Ankara Vaccine

Vaccine

Developed for
acute lymphoblastic leukemia · cytomegalovirus infection · diffuse large B-cell lymphoma · high grade B-cell lymphoma · mantle cell lymphoma
Investigated by
City of Hope Medical Center · National Cancer Institute (NCI)

Trials 6

today NCT07020533 · Ph 1 NCT06735690 · Ph 0 NCT06059391 · Ph 2 NCT05801913 · Ph 1 NCT05432635 · Ph 1 NCT03560752 · Ph 1
20192020202120222023202420252026202720282029
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 01 trial
Phase 0 NCT06735690 Dec 2025 → Mar 2029 expected acute lymphoblastic leukemia City of Hope Medical Center Recruiting No outcome recorded
Phase 14 trials
Phase 1 NCT07020533 May 2026 → May 2028 expected Hodgkins lymphoma, acute myeloid leukemia, chronic lymphocytic leukemia/small lymphocytic lymphoma, leukemia, myeloid, accelerated-phase +3 City of Hope Medical Center Recruiting No outcome recorded
Phase 1 NCT05801913 Sep 2023 → Mar 2028 expected high grade B-cell lymphoma City of Hope Medical Center Recruiting No outcome recorded
Phase 1 NCT05432635 Aug 2023 → Mar 2028 expected diffuse large B-cell lymphoma, mantle cell lymphoma City of Hope Medical Center Recruiting No outcome recorded
Phase 1 NCT03560752 Aug 2018 → Jan 2022 overdue Hodgkins lymphoma, acute myeloid leukemia, chronic lymphocytic leukemia/small lymphocytic lymphoma, cytomegalovirus infection +5 City of Hope Medical Center Active not recruiting No outcome recorded
Phase 21 trial
Phase 2 NCT06059391 Jul 2024 → Jan 2028 expected B-cell chronic lymphocytic leukemia, Hodgkins lymphoma, acute myeloid leukemia, chronic myeloid leukemia +2 City of Hope Medical Center Recruiting No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 7 sources stand behind the page.

FieldValueCited text
Known as Multi-peptide CMV-Modified Vaccinia Ankara Vaccine ClinicalTrials.gov intervention name — accepted as the source's own label NCT03560752 ↗
5

NCT07020533 ↗

NCT05432635 ↗

NCT05801913 ↗

NCT06735690 ↗

NCT06059391 ↗
Action Deplete “Vaccines such as CMV-MVA triplex are made from gene-modified viruses and may help the body build an effective immune response to kill cancer cells.” NCT05432635 ↗
Modality Vaccine “Triplex is a viral vectored recombinant vaccine expressing three immunodominant CMV antigens.” PMID 36594185 ↗ Jan 2023
Route Intramuscular “Given IM” NCT05432635 ↗